Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21895844 | 0.93 | POLG (0.55) | POLGPOLBPOLA1CACNA1FLMNA | |
| SCHEMBL454264 | 0.93 | POLG (0.55) | POLGPOLBPOLA1CACNA1FLMNA | |
| SCHEMBL23157013 | 0.93 | POLG (0.55) | POLGPOLBPOLA1CACNA1FLMNA | |
| SCHEMBL23157216 | 0.93 | POLG (0.55) | POLGPOLBPOLA1CACNA1FLMNA | |
| SCHEMBL543055 | 0.93 | POLG (0.60) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL543054 | 0.93 | POLG (0.60) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL19389365 | 0.85 | POLG (0.54) | POLGPOLBPOLA1CACNA1FLMNA | |
| SCHEMBL543438 | 0.85 | POLG (0.67) | POLGPOLBCACNA1FLMNAALB | |
| SCHEMBL21626043 | 0.85 | POLG (0.51) | POLGPOLBPOLA1CACNA1FLMNA | |
| SCHEMBL28165218 | 0.83 | POLB (0.70) | POLGPOLBPOLA1P2RY6P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | disclosed |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | PROTERA S.R.L. (IT) | 2008-12-04 | — | — | US | disclosed |
| EP-1778254-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | Protera S.R.L. (IT) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006013203-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | PROTERA S.R.L. (IT) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | TERT, POLRMT, POLI | POLG 42/4885POLB 8/4885POLA1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.